Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Eugene Komchuk
Eugene Komchuk

Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences

Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences
Castle honors lab innovation

Castle Biosciences is recognizing its laboratory professionals during Lab Week for their critical role in developing innovative diagnostic tests.

The company credits its laboratory teams with providing personalized information that supports patient care and improves health outcomes, particularly in the areas of skin cancer and melanoma.

Earlier this year, Castle Biosciences unveiled its new headquarters in Friendswood, Texas. The company said the move emphasizes its commitment to the local community. Castle has stated that the expanded facility supports future growth.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

The limits of progress: Why AI development could slow down
  • By Oleg Tkachenko
  • 3 hours ago
The limits of progress: Why AI development could slow down
Editors' Picks
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
  • By Dmytro Kharkov
  • 4 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
Editors' Picks
Tokens without buyers: Why NFT marketplaces are shutting down
  • By Mikhail Vnuchkov
  • Yesterday
Tokens without buyers: Why NFT marketplaces are shutting down
Editors' Picks
All Editors' Top Picks

Latest Castle News

Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026
  • By Oksana Koneva
  • Yesterday
Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026
Companies
#Castle
Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations
  • By Alena Volkova
  • 28.09.2026
Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations
Companies
#Castle
Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment
  • By Mikhail Vnuchkov
  • 25.09.2026
Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment
Companies
#Castle
All Castle News
  • Oleg Tkachenko
  • 3 hours ago
The limits of progress: Why AI development could slow down
  • Dmytro Kharkov
  • 4 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
  • Mikhail Vnuchkov
  • Yesterday
Tokens without buyers: Why NFT marketplaces are shutting down
  • Alena Volkova
  • Yesterday
Is it bad to be rich: Why billionaires are seen as villains
  • Olena Litvinenko
  • Yesterday
What is a national blockchain network and does the world need one?
  • Elena Nikulina
  • 4 min ago
Laura Shin: MediaMarkt Saturn halts Ledger wallet sales after implant report in Germany
  • Yaroslav Dmytrenko
  • 6 min ago
Copper remains resilient while other metals decline, Otavio (Tavi) Costa notes
  • Yulia Slavina
  • 15 min ago
Most bitcoin remains in self-custody despite institutionalization, Alex Thorn notes
  • Hanna Syniavska
  • 25 min ago
S&P 500 avoids 1% drop for over 50 trading days, Lance Roberts notes
  • Mikhail Vnuchkov
  • 30 min ago
Nominal yields reflect more than inflation expectations, Andreas Steno Larsen notes
Top News
  • Ivan Andriyenko
  • 2 hours ago
Gold slips below $4,150 as Fed rate outlook weighs on bullion
Gold slips below $4,150 as Fed rate outlook weighs on bullion
  • Andrey Mastykin
  • 3 hours ago
Lagarde sees no wider inflation spillover as energy prices surge
Lagarde sees no wider inflation spillover as energy prices surge
  • Dmytro Kharkov
  • 4 hours ago
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?
  • Olga Shendetskaya
  • 4 hours ago
Oil markets face new risks as Iran targets Gulf shipping routes
Oil markets face new risks as Iran targets Gulf shipping routes
  • Eugene Komchuk
  • 5 hours ago
Coinbase unveils plan to protect Bitcoin from quantum threats
Coinbase unveils plan to protect Bitcoin from quantum threats
Live News
  • Hanna Syniavska
  • Now
Goldman Sachs targets India and China as AI spending accelerates
  • Mykhailo Ihnatenko
  • Now
AMD stock tests $600 support as CPI raises volatility risk
  • Igor Krasulya
  • Now
LSEG boosts financial data analytics with Nvidia computing power
  • Eugene Komchuk
  • Now
Affluent Standard Chartered clients can now trade cryptocurrencies in UAE
  • Mykhailo Ihnatenko
  • Now
Ethereum price prediction: Can ETF inflows and whale buying revive momentum?
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers